お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:RAFプロトオンコジーンセリン/トレオニンプロテインキナーゼ:パイプラインレビュー(2020年上半期)
市場調査レポート
商品コード
949882

RAFプロトオンコジーンセリン/トレオニンプロテインキナーゼ:パイプラインレビュー(2020年上半期)

RAF Proto Oncogene Serine/Threonine Protein Kinase - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 91 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=109.72円
RAFプロトオンコジーンセリン/トレオニンプロテインキナーゼ:パイプラインレビュー(2020年上半期)
出版日: 2020年06月30日
発行: Global Markets Direct
ページ情報: 英文 91 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

RAFプロトオンコジーンセリン/トレオニンプロテインキナーゼ(プロトオンコジーンc-Raf/Raf1またはEC 2.7.11.1)のターゲット分子はおよそ18分子あり、そのうちおよそ13分子は企業が開発し、残りは大学・研究機関が開発しています。

当レポートは、RAFプロトオンコジーンセリン/トレオニンプロテインキナーゼ(プロトオンコジーンc-Raf/Raf1またはEC 2.7.11.1)について調査しており、製品・作用機序の概要、研究開発の概要、ライセンスおよび協業の詳細、開発活動、パイプライン製品の薬剤プロファイルなどの情報を提供しています。

目次

目次

  • 表のリスト
  • 図のリスト
  • イントロダクション
  • 調査範囲
  • 概要
  • 治療薬開発
    • 開発段階別
    • 治療領域別
    • 適応症別
    • 企業別
    • 大学・研究機関別
  • 治療評価
    • 作用機序別評価
    • 投与経路別評価
    • 分子タイプ別評価
  • 治療薬開発に関与する企業
    • Apollomics Inc
    • Bayer AG
    • DOT Therapeutics-1 Inc
    • Hanmi Pharmaceuticals Co Ltd
    • Jazz Pharmaceuticals Plc
    • Metagone Biotech Inc
    • Novartis AG
    • Redx Pharma Plc
    • Samjin Pharm Co Ltd
    • Verastem Inc
    • VG Life Sciences Inc
  • 薬剤プロファイル
    • (MG-005 +ソラフェニブ)
    • (MG-010 +ソラフェニブ)
    • APL-102
    • Belvarafenib
    • CKI-27、など
  • 注目のニュースとプレスリリース
  • 付録
    • 調査手法
    • 調査範囲
    • 2次調査
    • 1次調査
    • 専門家パネル検証
    • お問い合わせ
    • 免責事項
図表

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Apollomics Inc, H1 2020
  • Pipeline by Bayer AG, H1 2020
  • Pipeline by DOT Therapeutics-1 Inc, H1 2020
  • Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
  • Pipeline by Jazz Pharmaceuticals Plc, H1 2020
  • Pipeline by Metagone Biotech Inc, H1 2020
  • Pipeline by Novartis AG, H1 2020
  • Pipeline by Redx Pharma Plc, H1 2020
  • Pipeline by Samjin Pharm Co Ltd, H1 2020
  • Pipeline by Verastem Inc, H1 2020
  • Pipeline by VG Life Sciences Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
目次
Product Code: GMDHC2456TDB

Summary:

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report RAF Proto Oncogene SerineThreonine Protein Kinase - Pipeline Review, H1 2020, outlays comprehensive information on the RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - RAF proto-oncogene serine/threonine-protein kinase or proto-oncogene c-RAF is an enzyme is encoded by the RAF1 gene. Once activated the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2 which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. It plays an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology and Musculoskeletal Disorders which include indications Colorectal Cancer, Non-Small Cell Lung Cancer, Gastric Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Liver Cancer, Melanoma, Solid Tumor, Adenocarcinoma Of The Gastroesophageal Junction, Adenoid Cystic Carcinoma (ACC), Bladder Cancer, Breast Cancer, Chondrosarcoma, Ewing Sarcoma, Fibrosis, Glioblastoma Multiforme (GBM), Kidney Cancer (Renal Cell Cancer), Liposarcoma, Low-Grade Glioma, Lung Cancer, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Myelodysplastic Syndrome, Myelofibrosis, Osteosarcoma, Ovarian Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rhabdomyosarcoma, Sarcomas, Soft Tissue Sarcoma and Transitional Cell Cancer (Urothelial Cell Cancer).

Furthermore, this report also reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
  • The report reviews RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Overview
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
  • Apollomics Inc
  • Bayer AG
  • DOT Therapeutics-1 Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Jazz Pharmaceuticals Plc
  • Metagone Biotech Inc
  • Novartis AG
  • Redx Pharma Plc
  • Samjin Pharm Co Ltd
  • Verastem Inc
  • VG Life Sciences Inc
  • RAF Proto Oncogene Serine/Threonine Protein Kinase (Proto Oncogene c RAF or RAF1 or EC 2.7.11.1) - Drug Profiles
  • (MG-005 + sorafenib) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (MG-010 + sorafenib) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APL-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • belvarafenib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CKI-27 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.